Medication info
Ilyang Metformin Sustained-Release Tablets (Metformin Hydrochloride)

Ilyang Metformin Sustained-Release Tablets (Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Ilyang Pharmaceutical Co., Ltd.
Appearance
White rectangular tablets
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 201605005 · Approved 2016.08.18

Summary

Main use
Treatment of type 2 diabetes
Who takes it
Adults
Adult dose
The dose should be determined individually based on drug response and tolerability, and should not exceed the recommended maximum daily dose. - The usual initial dose is 500mg of extended-release metformin hydrochloride once daily with the evening meal. - Measure blood glucose after one week and adjust the dose. Gastrointestinal adverse reactions may improve with gradual dose escalation. The maximum dose is 2000mg per day. - Increase the dose by 500mg each week when escalating, up to a maximum of 2000mg per day with the evening meal. If glycemic control is not achieved with a maximum of 2000mg once daily, consider administering 1000mg twice daily; both doses should be taken with meals. - For patients already receiving metformin tablets, the initial dose of this formulation is the same as the daily dose of immediate-release metformin tablets. Switching to this formulation is not recommended for patients taking more than 2000mg per day of immediate-release metformin. - At initiation of treatment and during dose adjustment, measure fasting blood glucose to assess response to this medicine and determine the minimum effective dose. Measure blood glycated hemoglobin levels at approximately 3-month intervals. - The goal of treatment with this medicine, whether given as monotherapy or in combination with a sulfonylurea or insulin, is to reduce fasting blood glucose and blood glycated hemoglobin levels to normal or near-normal levels using the minimum effective dose. Patients with renal impairment This medicine may be used in patients with moderate stage 3a renal impairment (creatinine clearance [CrCl] 45≤~ <60ml/min or glomerular filtration rate (GFR) 45≤~ <60 mL/min/1.73 m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. - The starting dose is 500mg or 750mg once daily. The maximum daily dose is 1000mg. Renal function should be monitored closely every 3- 6 months. If creatinine clearance or glomerular filtration rate decreases to less than 45ml/min or 45ml/min/1.73m2, this medicine must be discontinued immediately.

Ingredients

Manufacturer
Ilyang Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of type 2 diabetes

  • Type 2 diabetes with insufficient blood sugar control
View approved original text

This medication is used to treat adult patients with Type 2 diabetes for whom diet and exercise alone are not sufficient for blood sugar control, especially those who are overweight. It can be used alone or in combination with other oral hypoglycemic agents or insulin to help improve blood sugar control.

How to take

Adult dose

The dose should be determined individually based on drug response and tolerability, and should not exceed the recommended maximum daily dose. - The usual initial dose is 500mg of extended-release metformin hydrochloride once daily with the evening meal. - Measure blood glucose after one week and adjust the dose. Gastrointestinal adverse reactions may improve with gradual dose escalation. The maximum dose is 2000mg per day. - Increase the dose by 500mg each week when escalating, up to a maximum of 2000mg per day with the evening meal. If glycemic control is not achieved with a maximum of 2000mg once daily, consider administering 1000mg twice daily; both doses should be taken with meals. - For patients already receiving metformin tablets, the initial dose of this formulation is the same as the daily dose of immediate-release metformin tablets. Switching to this formulation is not recommended for patients taking more than 2000mg per day of immediate-release metformin. - At initiation of treatment and during dose adjustment, measure fasting blood glucose to assess response to this medicine and determine the minimum effective dose. Measure blood glycated hemoglobin levels at approximately 3-month intervals. - The goal of treatment with this medicine, whether given as monotherapy or in combination with a sulfonylurea or insulin, is to reduce fasting blood glucose and blood glycated hemoglobin levels to normal or near-normal levels using the minimum effective dose. Patients with renal impairment This medicine may be used in patients with moderate stage 3a renal impairment (creatinine clearance [CrCl] 45≤~ <60ml/min or glomerular filtration rate (GFR) 45≤~ <60 mL/min/1.73 m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. - The starting dose is 500mg or 750mg once daily. The maximum daily dose is 1000mg. Renal function should be monitored closely every 3- 6 months. If creatinine clearance or glomerular filtration rate decreases to less than 45ml/min or 45ml/min/1.73m2, this medicine must be discontinued immediately.

Precautions

This medication can rarely cause serious lactic acidosis, which has been reported to lead to fatal cases. Caution is necessary when used with other diabetes medications as severe hypoglycemia may occur. It should not be prescribed to patients with moderate to severe renal impairment or conditions such as dehydration, severe infections, or acute myocardial infarction. It should also not be used in patients with acute or unstable heart failure, certain radiological examinations, drug hypersensitivity, or in patients with Type 1 diabetes. Patients with severe infections or major trauma should discontinue the oral intake until recovery and normalization of kidney function. Patients scheduled for surgery should stop using this medication 48 hours before surgery and can resume afterward once kidney function is confirmed to be normal. Caution is also required in patients with malnutrition, frailty, liver dysfunction, or excessive alcohol intake. Kidney function should be regularly monitored during treatment, especially in elderly patients or those with reduced kidney function. The risk of hypoglycemia is present, hence caution is needed for irregular meals, vigorous exercise, and interactions with other medications. Gastrointestinal symptoms (nausea, vomiting, diarrhea, etc.) are common at the beginning of treatment but usually adapt over time. If skin rashes or itching occur, administration should be stopped immediately and a physician consulted. Alcohol intake may affect lactate metabolism and increase risk, hence it should be avoided. During pregnancy, it may affect fetal growth and should be used cautiously under a doctor's judgment, while it is not recommended during breastfeeding. It is advisable not to use in children or adolescents under the age of 17, as safety and efficacy have not been established. In case of overdose, drug removal through blood dialysis is possible; immediate medical assistance should be sought. This medication should be taken strictly according to a doctor’s instructions, and the tablets should be swallowed whole without chewing or crushing. During treatment, blood sugar levels, kidney function, and vitamin B12 levels should be monitored regularly, and any unusual symptoms should be reported to healthcare professionals immediately.

Side effects

  • severe lactic acidosis
  • severe hypoglycemia
  • vitamin B12 deficiency
  • taste disturbance
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • erythema
Show 3 more
  • pruritus
  • urticaria
  • rash

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. Additionally, it should be kept in a location that avoids extreme heat or cold, ideally at a temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

White rectangular tablets

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.